Background: Tenofovir disoproxil fumarate (TDF) has been widely recommended as a first-line antiviral agent to treat chronic hepatitis B (CHB). Qingzhong and Viread, formulations of TDF commercialized by Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd and GlaxoSmithKline, respectively, have both been approved by the State Food and Drug Administration, China. This study analyzed the efficacy and safety of these 2 TDF agents in Chinese patients with CHB.
Introduction
Chronic infection with hepatitis B virus (HBV) is a worldwide health problem. It is estimated that at least 2 billion people are infected with HBV and that 240 million individuals have chronic HBV infections. [1] Sustained suppression of serum HBV DNA by nucleoside/nucleotide analogues (NAs) have been associated with the prevention of progression to liver decompensation and development of hepatocellular carcinoma. [2, 3] Tenofovir disoproxil fumarate (TDF) has been recommended by different guidelines as a first-line antiviral agent for the treatment of chronic hepatitis B (CHB) due to its superior efficacy and low resistance rates. [4] [5] [6] [7] Early trials conducted by Gilead Sciences showed the safety and efficacy of oral TDF, at a dose of 300 mg administered once daily, [8] [9] [10] [11] which notably also exhibited a low resistance rate. [10, 12, 13] TDF also exhibited a pharmacokinetic profile in healthy Chinese patients similar to that in patients in Western countries and was also generally welltolerated by healthy Chinese patients. [14] However, the long-term costs associated with patients treated with Viread (GlaxoSmithKline, Shanghai, China), the commercialized formulation of TDF, are high, which affects patient drug compliance and quality of daily life. Qingzhong, a generic version of Viread containing TDF, was developed by Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd (Jiangsu, China). Hence, we designed this phase 3 trial to evaluate the efficacy and safety of these 2 TDF agents in Chinese patients with CHB.
Materials and methods

Study design
This study was designed as a noninferiority trial and consisted of 2 stages (Fig. 1 ). In the first stage, a phase 3 clinical trial, conducted as a randomized (1:1), double-blind, double-dummy, controlled study was performed to compare Qingzhong (Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd), 300 mg once daily (Group A) with Viread (GlaxoSmithKline) 300 mg once daily (Group B) for up to 48 weeks in patients with CHB. All subjects were stratified by hepatitis B e antigen (HBeAg) status before being randomized into the treatment groups. Treatment assignments were allocated centrally by statisticians by permuted block sizes of 4 that were assigned within each site. Investigators at each site were responsible for patient enrollment. In the second stage, conducted as an elongation open-label study, all patients received Qingzhong 300 mg once daily for up to 240 weeks. In the first stage, patients returned to the clinic at 4, 12, 24, 36, and 48 weeks for vital signs evaluation, symptom reviews, and laboratory assessments including hematologic values, liver function tests, and HBV DNA level quantification and for documentation of any adverse events (AEs). HBV DNA was assayed using a secondgeneration polymerase chain reaction (PCR) quantitative assay with a lower limit of detection (LLOD) of 20 IU/mL (COBAS AmpliPrep/COBAS TaqMan HBV Test, Roche Molecular Systems, Pleasanton, CA).
This study was designed by the sponsor (Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd) in collaboration with the primary investigators. The sponsor collected the data and monitored the conduct of the study. Data were unblinded firstly to reveal patient grouping for statistical analysis after the database was locked. Independent statisticians performed the statistical analysis. After the statistical analysis was completed, a second unblinding was conducted to reveal the treatment administered to each patient in groups A and B. The primary investigator coordinated the writing of the manuscript with all the authors. All authors had access to the study data and reviewed and approved the final manuscript. Week 48
HBeAg-positive CHB
Week 240 The clinical trial was approved by the State Food and Drug Administration, China (2013L01048) and was registered with ClinicalTrials.gov (NCT02287857). The study was approved by the Ethics Committees of the 14 study sites, including Peking University First Hospital, China, and all procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments. Written informed consent was obtained from all study participants.
Study population
Patients were enrolled from 14 sites located in Beijing, Shanghai, Chengdu, Chongqing, Guangzhou, Nanjing, and Zhengzhou, China, and followed-up from September 2014 to October 2019. The inclusion criteria were having a diagnosis of HBeAg (-) or HBeAg (+) CHB infection [HBsAg (+) for at least 6 months] and no history of previous use of any antiviral agents (interferon, thymosin alpha-1, or NAs); being 18 to 65 years old; having HBV viral load ≥2Â10 4 IU/mL in those who were HBeAg(+) or ≥2Â10 3 IU/mL in those who were HBeAg (À); alanine aminotransferase (ALT) ≥2 and 10 times the upper limit of normal (ULN) and serum total bilirubin 2.5 times the ULN; prothrombin activity ≥60% or prolongation of prothrombin time 3 seconds; leukocyte count ≥3.5 Â 10 9 /L; platelet count ≥80 Â 10 9 /L; serum albumin ≥35 g/L; serum creatinine 1.0 times the ULN; normal serum phosphorus.
Key exclusion criteria included coinfection with another virus (such as human immunodeficiency virus type 1, hepatitis A, C, D, or E virus), evidence of hepatocellular carcinoma or cirrhosis of the liver, pregnant or lactating women, or comorbid severe cardiovascular, urinary, endocrine, bloodborne, immunological, or mental diseases. Patients allergic to TDF were also excluded from the study.
Endpoints
The primary efficacy endpoint was decline of plasma HBV DNA levels at week 48. Secondary efficacy endpoints included the proportion of patients with undetectable HBV DNA (<20 IU/mL) and the percentage of patients who achieved HBV DNA levels <69 IU/mL (<400 copies/mL). Based on the fact that HBV DNA levels <400 copies/mL were defined as being undetectable in a previous study on TDF, [8] the normalization of serum ALT (an ALT value no greater than the ULN), HBsAg/HBeAg loss or seroconversion defined as HBsAg/HBeAg loss and the appearance of hepatitis B surface antibody (antiHBs)/hepatitis B envelope antibody (antiHBe), and virological breakthrough, that is, a confirmed HBV DNA level ≥69 IU/mL after a documented level of <69 IU/mL or a confirmed log 10 increase of ≥1.0 from the nadir level were considered appropriate endpoints.
Safety analysis
The safety analysis included data from all 338 treated patients who received at least 1 dose of a study drug during this doubleblind study period. All AEs including serious adverse events (SAEs) were recorded. An SAE was defined by one of the following: death, fatal injury, development of a disability, hospitalization, or reduced ability to work. Safety parameters including patient chief complaints, abnormal signs observed by doctors, vital signs values, and blood levels including white blood cell counts, red blood cell counts, platelet counts, liver enzymes, serum phosphate, creatinine, and blood urea nitrogen were evaluated at every visit. Bone mineral density was assessed by dual-energy x-ray absorptiometry scan at weeks 0 and 48. Any parameter outside the normal range was evaluated by the research physician for clinical significance, recorded in the AE report form, and judged for its severity and potential relationship to the study drug. Patients who experienced an SAE were removed from the trial unless the adverse effects were not related to the drug. Patients who showed poor efficacy (defined as a decrease of <1 log IU/mL in the HBV DNA level at 24 weeks), virological breakthrough, or clinical resistance to TDF received additional administration of entecavir 0.5 mg once daily and were removed from the trial.
Laboratory tests
Virological and serological parameters were determined centrally by the Laboratory of Virology, Department of Infectious Diseases, Peking University First Hospital (including the baseline). HBV DNA was assayed using the second-generation PCR quantitative assay with an LLOD of 20 IU/mL and for HBeAg and hepatitis B e antibody by enzyme immunoassay, using the corresponding Abbott AxSYM microparticle enzyme immunoassays (Abbott Laboratories, Chicago, IL). The biochemical parameters were determined by the local laboratory.
Statistical analysis
Continuous variables were expressed as means with standard deviations or medians with interquartile ranges, where applicable. Categorical variables were expressed as counts and percentages. To compare continuous variables, we used t tests or Wilcoxon rank sum test, where applicable. Comparison of categorical data between the 2 groups was performed using the Chi-square test or Fisher exact test, where applicable. A 2-tailed P value <.05 was considered statistically significant. These statistical analyses were performed using SAS software version 9.4 (SAS Institute Inc, Cary, NC).
According to the statistical data of the early TDF efficacy trial, [8] unilateral a = 0.05, b = 0.20, and an equivalent limit d = 1.0 log 10 IU/mL were used. The statistical analysis was performed using a calculation formula of equivalent sample sizes in the 2 groups (PASS software calculation; PASS Technology, London, UK), and the 2 groups both needed no <68 patients. Considering the drop-out factors and the length of the randomization group, the minimal sample size was determined to be 240 (120 patients in group A and 120 patients in group B). Account for potential loss to follow-up, the sample size was appropriately increased.
Results
Baseline characteristics
Of the 401 patients who were screened, 341 (171 in group A and 170 in group B) were enrolled and randomized and received, in blinded fashion and 338 patients treated, at least 1 dose of the study drug. Of the 341 patients, 8 (2.35%) were excluded from the full analysis set (FAS) due to loss of data before the therapy or failure to meet the inclusion criteria. Three patients were also excluded from the FAS because they refused to participate in the study before therapy initiation. Accordingly, 330 patients (161 in group A and 169 in group B) were included in the FAS (Fig. 2) . The 2 groups were well balanced at baseline (Table 1) . Table 4 ). The rate of ALT normalization increased as duration of therapy increased.
Virological breakthrough.
One patient developed virological breakthrough in each group by week 48. Both patients were HBeAg (+). Entecavir 0.5 mg once daily was added to their regimens, and they both subsequently experienced a decrease in HBV DNA levels. We subsequently sequenced the HBV reverse transcriptase region from the serum samples of these patients and performed mutation testing for rtL80, rtV84, rtS85, rtI169, rtV173, rtL180, rtA181, rtT184, rtA194, rtS202, rtM204, rtV214, rtQ215, rtN236, and rtM250, which are well-characterized NAs-resistance point mutations, at weeks 0, 4, 12, 24, 36, and 48. None of the samples showed evidence of resistance mutations.
Safety analysis
In total, 338 patients were included in the safety analysis set. The frequency of AEs during treatment was similar in both groups 
Discussion
The number of Chinese patients with CHB utilizing TDF has increased because of its superior efficacy and low resistance rate, especially among patients that have failed treatment with other NAs. Given that Chinese national policy covers domestic drugs at a cheaper price and higher reimbursement ratio and coverage, a noninferior domestic generic of TDF may be better for long-term treatment of Chinese patients with CHB. Hence, this study analyzed the efficacy and safety of 2 TDF agents, Viread and Qingzhong, in Chinese patients with CHB and found that there were no significant differences in efficacy and safety profiles between both drugs (P > .05) during the 48-week administration.
Regarding the primary endpoint of this study, the mean reduction in HBV DNA levels achieved was similar between the 2 groups whether they were HBeAg (+) or HBeAg (À). Both groups had 1 patient with a virological breakthrough. These 2 patients received entecavir 0.5 mg once daily and were removed from the trial. Notably, their HBV DNA levels decreased after the addition of entecavir to their treatment regimen. With respect to viral suppression, there was no significant difference between the 2 groups. Our study adopted a highly sensitive test, namely the COBAS TaqMan HBV assay (LLOD 20 IU/mL) to measure serum HBV DNA levels and showed that group B was not significantly better than group A (P > .05). Compared with an early TDF efficacy trial, [8] where 76% of the patients who were HBeAg (+) and 93% of the patients who were HBeAg (À) achieved HBV DNA levels <69 IU/mL, respectively, our study showed the noninferior efficacy [group A: 80.70% of HBeAg (+) patients and 93.62% of HBeAg (À) patients versus group B: 77.97% of HBeAg (+) patients and 98.04% of HBeAg (À) patients, P > .05; (Table 3) ]. Similar rates of HBeAg loss and HBeAg seroconversion were achieved in both groups. Our better findings could be related to sampling variations among treatment-naïve patients. All our results show the noninferior Although previous TDF-related renal impairment has been previously reported, [15] serum creatinine levels were stable in either group at 48 weeks into our study, which is similar to the findings of an early TDF efficacy trial. [8] One study participant who developed hypophosphatemia without pathological fracture in group A had shown a lower concentration of serum phosphorus before treatment compared with other patients. He was offered phosphorus treatment based on previous studies of tenofovir-associated Fanconi syndrome [16] [17] [18] [19] and was monitored closely. The research physician subsequently decided to remove this patient from the trial based on changes in his blood phosphorus levels and skeletal symptoms and signs observed (osteopathic and osteoporosis requiring intervention).
Hence, TDF showed both efficacy and safety in Chinese patients with CHB at 48 weeks. However, there were some limitations to the present study. First, the results included only 48 weeks of follow-up without long-term treatment data. The incidence of AEs observed in the present study cannot ensure the long-term safety of the monotherapy. Fortunately, after week 48, patients could enroll in long-term open-label studies on Qingzhong for an additional 4 years. Second, serum creatinine, the most widely used clinical indicator of kidney injury, has low sensitivity. Hence the incidence of kidney injury in this study could have been underestimated. Follow-up studies should apply more sensitive biomarkers [20] [21] [22] to monitor for kidney injury. A study on sensitive biomarkers of kidney injury is currently underway by our research group.
Conclusions
In conclusion, this 48-week phase 3 trial showed that TDF was an effective and safe choice for the treatment of HBeAg (À) and HBeAg (+) CHB in Chinese patients. Viread and Qingzhong showed noninferior efficacy and safety in Chinese patients with CHB. TDF should be considered for the treatment of CHB, especially in NA-naïve adults without renal or bone diseases.
